<p>The Evolving Treatment of Diabetic Retinopathy</p>
Sam E. Mansour, David J. Browning, Keye Wong et al.
Research Article — Peer-Reviewed Source
Original research published by Mansour et al. in Clinical ophthalmology. Redistributed under Open Access — see publisher for license terms. MedTech Research Group provides these references for informational purposes. We do not conduct original research. All studies are the work of their respective authors and institutions.
Pharmacotherapy, both ocular and systemic, will be the primary mode of intervention in the management of DR and DME in many cases when cost and treatment burden are less constrained. Conventional laser therapy has become a secondary intervention in these instances, but remains a first-line option when cost and treatment burden are more constrained. Results with subthreshold laser appear promising but will require more rigorous study to establish its role as adjunctive therapy. Evidence to support an optimal integration of the various treatment options is lacking. Central to the widespread adoption of any therapeutic regimen for DR and DME is substantiation of safety, efficacy, and cost-effectiveness by a body of sound clinical trials.
Full text is available at the publisher.
Read at Publisher| DOI | 10.2147/opth.s236637 |
| Journal | Clinical ophthalmology |
| Year | 2020 |
| Authors | Sam E. Mansour, David J. Browning, Keye Wong, Harry W. Flynn, Abdhish R. Bhavsar |
| License | Open Access — see publisher for license terms |
| Citations | 226 |